fingolimod (FTY720)

Phase 1/2Completed
0 watching 0 views this week Active
41
Hype Score

Development Stage

Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Rett's Syndrome

Conditions

Rett's Syndrome

Trial Timeline

Aug 1, 2013 → Apr 1, 2018

About fingolimod (FTY720)

fingolimod (FTY720) is a phase 1/2 stage product being developed by Novartis for Rett's Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT02061137. Target conditions include Rett's Syndrome.

Hype Score Breakdown

Clinical
13
Activity
8
Company
10
Novelty
4
Community
3

Clinical Trials (3)

NCT IDPhaseStatus
NCT02061137Phase 1/2Completed
NCT01498887ApprovedCompleted
NCT00731523Phase 1Completed

Competing Products

4 competing products in Rett's Syndrome

See all competitors
ProductCompanyStageHype Score
Esomeprazole + Aspirin + RofecoxibAstraZenecaApproved
85
Esomeprazole + LansoprazoleAstraZenecaApproved
85
Esomeprazole MagnesiumAstraZenecaApproved
85
ChemotherapyPacific BiosciencesPre-clinical
15